Schöttli Demonstrating Latest Medical and Specialty Closure Moldmaking Technology

Husky Injection Molding Systems announced that Schöttli will be exhibiting at the upcoming Chinaplas 2014 tradeshow (April 23 – 26, Shanghai, China). The Schöttli booth will focus on showcasing the company’s latest mold technology for select medical and specialty closure applications.

Husky Injection Molding Systems today announced that Schöttli, recently acquired in December 2013, will be exhibiting at the upcoming Chinaplas 2014 tradeshow (April 23 – 26, Shanghai, China). The Schöttli booth will focus on showcasing the company’s latest mold technology for select medical and specialty closure applications.
 
“Chinaplas has always been an important show for Schöttli and we are very excited to be exhibiting this year together with Husky,” said Thomas Anderegg, President of the Schöttli Group. “Asia Pacific is a growing market, particularly for medical molds, and we are looking forward to the opportunity to connect with our customers in this region and demonstrate the combined capabilities of Schöttli and Husky.”
 
By gaining a detailed understanding of our customer’s needs at the tooling level, Schöttli has been able to focus on specific applications and develop mold technology that enables customers to bring the highest quality medical products to market. The Schöttli exhibit will showcase the company’s latest mold making technology for select medical applications, including syringes, infusion/transfusion products, diagnostic systems and feminine care items. Also featured, will be Husky’s unique EASYcube mold technology, which is designed to provide the best platform for molding multi-material closures.
 
With the recent acquisition of Schöttli, Husky’s goal is to gain deeper mold making knowledge in focused medical applications, as well as develop the expertise to build the strongest melt delivery system in the medical market. In addition, Schöttli complements Husky’s existing closures business and will extend the company’s presence in established and emerging markets.